New Anti-CARMA Antibody Series Released by AnaSpec
San Jose, CA, June 19, 2008 --(PR.com)-- AnaSpec has introduced a new series of IHC validated antibodies, Anti-CARMA/CARD/Bimp antibodies.
CARMA proteins are scaffold molecules that belong to the membrane-associated guanylate kinase-like (MAGUK) and the caspase-associated recruitment domain (CARD) protein families. They play critical role in antigen receptor signaling pathways.1-4 CARMA-1 (CARD-11) CARMA-2 (CARD-14), and CARMA-3 (CARD-10) share homologous sequence and functions but are found in different tissues. CARMA1 is predominantly located in lymphoid tissue.5 CARMA-1 protein associates with lipid rafts1 and interacts with Bcl10, that is required for activation of TCR induced NFkB signaling pathway.1,2,4 Specifically, CARMA-1 N-terminal CARD domain binds to Bcl10 CARD motif.5 It is also essential for protein-induced IL-2 and INF-γ production.2 CARMA-2 is mostly found in placenta.5 CARMA-2 protein induces NFκB activation; however, its signaling pathway it is not yet known.5 CARMA-3 is most abundant in nonhematopoietic cells.5 CARMA-3 protein physically associates with IKK complex and induces NFκB activation via LPA signaling pathway.7 CARMA genes deactivation studies in mice resulted in reduced immunoglobulin levels and absence of TCR-induced NFκB activation.4,6,7 This suggests that CARMA mutations may lead to adaptive and innate immunity malfunction.
Immunohistochemistry of these antibodies was performed by an anatomic pathologist on formalin-fixed, paraffin-embedded human or mouse tissues. Table 1 summarizes the IHC results. At least 22 different human or mouse tissues or cell types, including positive and negative tissues were used for each antibody tested. Dilutions of the antibodies at 2.5, 5, 10 and 20 ug/ml were tested, with the optimal concentration found to be at 10 ug/ml. These antibodies, provided at 50 ug, are sufficient for at least 5 IHCs. Moderate to strong staining with minimal background staining at the expected target tissues were observed for the antibodies. A representative image from a positively stained tissue is shown for each antibody. It shows the localization of the antibody as the precipitated red signal, with a hematoxylin purple nuclear counterstain.
Anti-CARMA Antibodies:
Anti-CARMA-1/CARD-11, human, Cat# 54982
Anti-CARMA-1/CARD-11, mouse, Cat# 54985
Anti-CARMA-2/CARD-14,human, Cat# 54983
Anti-CARMA-3/CARD-10,human, Cat# 54984
Anti-CARMA-3/CARD-10, mouse, Cat# 54987
Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry.
For more information, visit www.anaspec.com
References
1. Gaide, O et al. Nat. Immunology 3: 836 (2002).
2. Hara, H. et al. JEM, 200, 1167 (2004).
3. Narayan, P. et al. Mol Cell Bio 26, 2327 (2006).
4. Egawa T. et al. Current Biology 13, 1252 (2003).
5. Grabiner, B. et al. Genes and Dev. 21, 984 (2007).
6. Newton, K. et al. Current Biology 13, 1247 (2003).
7. Stilo R. et al. J. Biol. Chem.279: 34323 (2004).
###
CARMA proteins are scaffold molecules that belong to the membrane-associated guanylate kinase-like (MAGUK) and the caspase-associated recruitment domain (CARD) protein families. They play critical role in antigen receptor signaling pathways.1-4 CARMA-1 (CARD-11) CARMA-2 (CARD-14), and CARMA-3 (CARD-10) share homologous sequence and functions but are found in different tissues. CARMA1 is predominantly located in lymphoid tissue.5 CARMA-1 protein associates with lipid rafts1 and interacts with Bcl10, that is required for activation of TCR induced NFkB signaling pathway.1,2,4 Specifically, CARMA-1 N-terminal CARD domain binds to Bcl10 CARD motif.5 It is also essential for protein-induced IL-2 and INF-γ production.2 CARMA-2 is mostly found in placenta.5 CARMA-2 protein induces NFκB activation; however, its signaling pathway it is not yet known.5 CARMA-3 is most abundant in nonhematopoietic cells.5 CARMA-3 protein physically associates with IKK complex and induces NFκB activation via LPA signaling pathway.7 CARMA genes deactivation studies in mice resulted in reduced immunoglobulin levels and absence of TCR-induced NFκB activation.4,6,7 This suggests that CARMA mutations may lead to adaptive and innate immunity malfunction.
Immunohistochemistry of these antibodies was performed by an anatomic pathologist on formalin-fixed, paraffin-embedded human or mouse tissues. Table 1 summarizes the IHC results. At least 22 different human or mouse tissues or cell types, including positive and negative tissues were used for each antibody tested. Dilutions of the antibodies at 2.5, 5, 10 and 20 ug/ml were tested, with the optimal concentration found to be at 10 ug/ml. These antibodies, provided at 50 ug, are sufficient for at least 5 IHCs. Moderate to strong staining with minimal background staining at the expected target tissues were observed for the antibodies. A representative image from a positively stained tissue is shown for each antibody. It shows the localization of the antibody as the precipitated red signal, with a hematoxylin purple nuclear counterstain.
Anti-CARMA Antibodies:
Anti-CARMA-1/CARD-11, human, Cat# 54982
Anti-CARMA-1/CARD-11, mouse, Cat# 54985
Anti-CARMA-2/CARD-14,human, Cat# 54983
Anti-CARMA-3/CARD-10,human, Cat# 54984
Anti-CARMA-3/CARD-10, mouse, Cat# 54987
Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry.
For more information, visit www.anaspec.com
References
1. Gaide, O et al. Nat. Immunology 3: 836 (2002).
2. Hara, H. et al. JEM, 200, 1167 (2004).
3. Narayan, P. et al. Mol Cell Bio 26, 2327 (2006).
4. Egawa T. et al. Current Biology 13, 1252 (2003).
5. Grabiner, B. et al. Genes and Dev. 21, 984 (2007).
6. Newton, K. et al. Current Biology 13, 1247 (2003).
7. Stilo R. et al. J. Biol. Chem.279: 34323 (2004).
###
Contact
AnaSpec, Inc.
Ping Yang
408-452-5055
www.anaspec.com
Ping Yang
408-452-5055
www.anaspec.com
Contact
Categories